ePrints

Neutralising antibody potency against SARS-CoV-2 wild-type and Omicron BA.1 and BA.4/5 variants in infliximab and vedolizumab treated patients with inflammatory bowel disease after three doses of COVID-19 vaccine (CLARITY IBD): a prospective multicentre cohort study (CLARITY)

Lookup NU author(s): Professor Chris LambORCiD

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Publication metadata

Author(s): Liu Z, Le K, Zhou X, Alexander JL, Lin S, Bewshea C, Chanchlani N, Nice R, McDonald TJ, Lamb CA, Sebastian S, Kok K, Lees CW, Hart AL, Pollok RC, Boyton RJ, Altmann DM, Pollock KM, Goodhand JR, Kennedy NA, Ahmad T, Powell N

Publication type: Article

Publication status: Published

Journal: The Lancet Gastroenterology and Hepatology

Year: 2023

Volume: 8

Issue: 2

Pages: 145-156

Print publication date: 01/02/2023

Online publication date: 05/12/2022

Acceptance date: 10/11/2022

Date deposited: 10/11/2022

ISSN (print): 2468-1253

ISSN (electronic): 2468-1156

Publisher: The Lancet Publishing Group

URL: https://doi.org/10.1016/S2468-1253(22)00389-2

DOI: 10.1016/S2468-1253(22)00389-2

Data Access Statement: The data of this study are available under a transfer agreement from the corresponding author based on a reasonable request. There will be limitations on how data can be used or how long data will be available for.

Altmetrics

Funding

Share